// App-Quantinova.ai

TPS634 : Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).

Researchers

Presenter

  • Rishi Surana

Principal Investigators

  • J. Jack Lee

  • Brandon George Smaglo

  • Dan Zhao

  • Michael Sangmin Lee

  • Robert A. Wolff

  • Michael J. Overman

  • Jason Willis

  • Channing J. Der

  • Shubham Pant

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Pharmacology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Oncology (ONC)

Disease

  • Metastatic pancreatic adenocarcinoma

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Hydroxychloroquine

  • Binimetinib

Outcome

  • N/A

Study Design

  • Fixed Dose

  • Single Arm

  • Cohort

  • Single Center

Phase

  • I

Study Id's

  • NCT04132505

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved